To soften impacted faeces.
Innovation Pharmaceuticals reports that the Company has executed a license agreement with Alfasigma S.p.A (�Alfasigma�) to develop and commercialize locally-administered...
Ulcerative Colitis: For the treatment of mild to moderate acute exacerbations. For the maintenance of remission. Crohn's ileo-colitis For the maintenance of remission.
Ulcerative colitis : For the treatment of mild to moderate acute exacerbations. For the maintenance of remission. Crohn's ileo-colitis : For the maintenance of remission.
Objective: We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL vs. foam vehicle.
Arcutis Biotherapeutics, Inc. announced new data from the STRATUM pivotal Phase III trial investigating roflumilast foam as a potential treatment for children ages 9 and above and adults with moderate to severe seborrheic dermatitis were presented orally at the Academy of Dermatology and Venereology (EADV) Congress.
Arcutis Biotherapeutics announced positive topline results from the ARRECTOR Pivotal Phase III trial evaluating roflumilast foam 0.3%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents with scalp and body psoriasis.